With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like cancer, there’s a lot of pressure to optimize these therapies. This is especially true for therapies involving chimeric antigen receptor (CAR) T cells, which so far required a cumbersome process of extracting the patient’s T cells, modifying them ex vivo and returning the now CAR T cells to the patient’s body. After a recently published study, it seems that we may see in vivo CAR T cell therapy become reality, with all the ease of getting a vaccine shot.
We covered CAR T cells previously in the context of a way to prevent T cell exhaustion and making them more effective against certain tumors. This new study (paywalled) by [Theresa L. Hunter] et al. as published in Science demonstrates performing the CAR manipulation in vivo using CD8+ T cell targeting lipid nanoparticles containing mRNA to reprogram these T cells directly.
In rodent and non-human primate studies a clear effect on tumor control was demonstrated, with for auto-immune diseases the related B cells becoming effectively depleted. Although it’s still a long way off from human trials and market approval, this research builds upon the knowledge gained from existing mRNA vaccines, raising hopes that one day auto-immune or cancer therapy could be as simple as getting a cheap, standardized shot.
This articles is written by : Fady Askharoun Samy Askharoun
All Rights Reserved to Amznusa www.amznusa.com
Why Amznusa?
AMZNUSA is a dynamic website that focuses on three primary categories: Technology, e-commerce and cryptocurrency news. It provides users with the latest updates and insights into online retail trends and the rapidly evolving world of digital currencies, helping visitors stay informed about both markets.
